Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFer: pembrolizumab and radiotherapy in early-stage favorable classic Hodgkin lymphoma
2024-520138-31-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Progression-free survival at 1 year. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2024-520138-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520138-31-00.